Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 3:S1071-9164(25)00102-2.
doi: 10.1016/j.cardfail.2025.01.027. Online ahead of print.

Heterogeneity in Treatment Effects in the Reduction of Dietary Sodium to Less Than 100 mmol in Heart Failure (SODIUM-HF): A Secondary Post Hoc Analysis

Fernando G Zampieri  1 , Sarah Rathwell  2 , Finlay A McAlister  2 , Heather Ross  3 , Jorge Escobedo  4 , Clara Saldarriaga  5 , Eloisa Colin-Ramirez  6 , Richard W Troughton  7 , Peter Macdonald  8 , Wendimagegn Alemayehu  2 , Justin A Ezekowitz  9 ; SODIUM-HF Investigators
Affiliations
Free article

Heterogeneity in Treatment Effects in the Reduction of Dietary Sodium to Less Than 100 mmol in Heart Failure (SODIUM-HF): A Secondary Post Hoc Analysis

Fernando G Zampieri et al. J Card Fail. .
Free article

Abstract

Background: SODIUM-HF (Study of Dietary Intervention of Sodium Under100 mmol in Heart Failure) compared usual care with dietary sodium restriction in patients with heart failure (HF) and produced neutral results for the primary endpoint. Heterogeneity in treatment effects (HTE) analysis could enhance the original findings.

Objective: Explore the presence of HTE in the SODIUM-HF trial using a risk-effect-based approach.

Methods: HTE was assessed using a risk-based approach based on the Meta-Analysis Global Group in Chronic (MAGGIC) HF risk score. Interaction between MAGGIC quartiles and outcomes was assessed using a Bayesian regression model with neutral priors. The primary endpoint was the same for the original trial (composite of cardiovascular-related admission to hospital, cardiovascular-related emergency department visit, or all-cause death within 12 months in the intention-to-treat population); KCCQ was the secondary endpoint.

Results: Were included 806 patients. MAGGIC quartiles used for the risk-based analyses were 0.036 to 0.102 (low), >0.102 to 0.147 (medium-low), >0.147 to 0.209 (medium-high), and >0.209 to 0.591 (high). There was very strong evidence for the interaction between MAGGIC quartile and intervention (Bayes factor of 68). There was a strong suggestion of association between intervention arm and a lower occurrence of the primary endpoint for the medium-low MAGGIC quartile (>0.98 probability), and a suggestion that the intervention was associated with more frequent occurrence of the primary endpoint in the high MAGGIC quartile (probability of benefit of 0.06). Suggestion of HTE was also found for KCCQ with a strong suggestion of benefit for the intervention for those in the lowest MAGGIC quartiles.

Conclusions: HTE effects in the SODIUM-HF trial is probable. Further trials in sodium retention may benefit by incorporating this information.

Keywords: Nutrition; heart failure; heterogeneity in treatment effects; salt restriction.

PubMed Disclaimer

Conflict of interest statement

Disclosures JAE is supported by the Alberta Health Services (AHS) Chair in Cardiac Sciences; reports research support for trial leadership from Bayer, Merck & Co, Novo Nordisk, Cytokinetics, Applied Therapeutics, and American Regent; reports honoraria for consultancy from AstraZeneca, Boehringer Ingelheim, Novo Nordisk, Otsuka, Bayer, and Novartis; and serves as an advisor to US2.ai. FGZ has received consulting fees from Baxter (USA) and Bactiguard (Sweden) and grants from Ionis Pharmaceutics (USA) paid to their former institution, all unrelated to this work. All other authors report no conflicts of interest.

LinkOut - more resources